Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2

Retrovirology(2015)10.1186/s12977-015-0146-8Source: DataRank Database

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2 is a research paper published in Retrovirology (2015). On theSindex it has a DataRank of 0.550. It has been cited 38 times.

N/A

0.550DataRank · unranked

Scored on demand from live citation data

38 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)OA: goldTopics (28)IDs (PubMed, PMC)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.550

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (7)

Robert A Smith,Dana N Raugi,Charlotte Pan,Papa Salif Sow ORCID,Moussa Seydi ORCID

Live enrichment

PubMed:25808007 PMC:PMC4328052

NIAID NIH HHS

Grant: 2R01-AI060466

NIAID NIH HHS

Grant: P30 AI027757

NIAID NIH HHS

Grant: R01 AI060466

National Institutes of Health

Grant: 5R01AI060466-10

Antiretroviral Therapy for HIV-2 Infection in Senegal

National Institutes of Health

Grant: 5P30AI027757-18

University of Washington Center for AIDS Research

National Institutes of Health

Grant: 3P30AI027757-36S1

University of Washington/Fred Hutch Center for AIDS Research

goldLicense: CC BY

publisherhttp://link.springer.com/content/pdf/10.1186/s12977-015-0146-8.pdf

publisherhttp://link.springer.com/article/10.1186/s12977-015-0146-8/fulltext.html

publisherhttp://link.springer.com/content/pdf/10.1186/s12977-015-0146-8

Unpaywallhttps://retrovirology.biomedcentral.com/counter/pdf/10.1186/s12977-015-0146-8

Europe_PMChttps://europepmc.org/articles/PMC4328052

Fields of Study

0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

HumansHIV-1HIV-2OxazinesPiperazinesPyridonesHeterocyclic Compounds, 3-RingAnti-HIV AgentsMicrobial Sensitivity TestsDrug Resistance, ViralDolutegravir

Keywords

Anti-HIV AgentsPyridonesShort ReportMicrobial Sensitivity TestsPiperazinesInfectious DiseasesDolutegravirVirologyDrug Resistance, ViralHIV-2OxazinesHIV-1HumansHeterocyclic Compounds, 3-Ring

Sustainable Development Goals

SDG 3: 3. Good healthSDG 13: 13. Climate action

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2

FAIR Checklist

DataRank Breakdown

Authors (7)

Funding (6 grants)

Open Access

Topics

Annotations (Europe PMC)